MedTrace Logo

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 477

Last updated 2026-01-07

No results posted yet for this study

Summary

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Conditions

  • Blepharitis

Interventions

DRUG

Pimecrolimus 0.3% Ophthalmic Ointment

Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.

DRUG

Placebo Ophthalmic Ointment

Placebo will be applied twice a day to both eyelid margins.

Sponsors & Collaborators

  • Famy Life Sciences, a Viatris Company

    lead INDUSTRY

Principal Investigators

  • Marian Macsai, MD · Viatris Eye Care Division

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-22
Primary Completion
2025-09-09
Completion
2025-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06400511 on ClinicalTrials.gov